Molecular Marker as a Prognostic Indicator in Head and Neck Cancer Patients

  • AS Kirthi Koushik
  • KS SandeepEmail author
  • DL Rahul
  • Ram Charith Alva
Original Article


Head and neck cancer forms the major burden of cancer in the developing countries. Despite advancement in the treatment approach of head and neck cancer in terms of surgery, chemotherapy and radiotherapy overall long-term survival remains low due to uncontrollable persistent and recurrent disease. This low survival rate has demanded for the need for newer treatment approaches and prognostic markers. In a previously published study “impact of molecular predictors on the response rates in head and neck Cancer patients” by Koushik et al. assessed the impact of molecular markers like HPV, P53, and EGFR status along with other prognostic factors like tobacco use, age, sex, and socioeconomic status on response to treatment of head and neck cancer patients. Our present study is intent to provide update of the impact of those molecular markers on survival. Objective of our study is to correlate the HPV, EGFR, and P53 status with the survival rate of the head and neck cancer patients. Twenty-five histologically proven head and neck cancer patients were assessed for HPV, EGFR, and P53 status who underwent chemoradiation to a dose of 66 Gy in 33 fraction along with weekly cisplatin of 40 mg/m2, and all treated patients were followed up to a minimum of 3 years and analyzed for the survival. We found that 3-year survival for complete responders after treatment is 61.5% and partial responders, 57.1%; stable disease is 33.3%, and progressive disease is 0%. A 3-year survival for HPV-positive patients is 57.4% (p = 0.973), EGFR-mutated patients is 47.62% (p = 0.593), and P53-mutated patients is 57.89% (p = 0.378).


Molecular marker Head and neck cancer Survival 



  1. 1.
    Garden AS, Harris J, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS, Ang KK (2008) Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys 71:1351–1355CrossRefGoogle Scholar
  2. 2.
    Ang KK, Berkey BA, Tu X, Zhang H-Z, Katz R, Hammond EH et al (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 15:7350–7356Google Scholar
  3. 3.
    Sathyamurthy A, Koushik ASK, Gowri M, Janaki MG, Kilara N, Ponni TRA et al (2016) Impact of molecular predictors on the response rates in head and neck cancer patients – an observational study. Indian J Surg Oncol 7(4):380–385 Available from:CrossRefGoogle Scholar
  4. 4.
    SEER Cancer Statistics Review 1975–2001 - Previous Version - SEER Cancer Statistics. Accessed 27 Aug 2018
  5. 5.
    Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 58(1):5–13Google Scholar
  6. 6.
    Sherr CJ, McCormick F (2002) The RB and p53 pathways in cancer. Cancer Cell 2(2):103–112CrossRefGoogle Scholar
  7. 7.
    Smith EM, Wang D, Kim Y, Rubenstein LM, Lee JH, Haugen TH et al (2008) p16INK4a Expression, human papillomavirus, and survival in head and neck cancer. Oral Oncol 44(2):133–142CrossRefGoogle Scholar
  8. 8.
    Geisler SA, Olshan AF, Weissler MC, Cai J, Funkhouser WK, Smith J et al (2002) p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 8(11):3445–3453PubMedGoogle Scholar
  9. 9.
    Klussmann JP, Gültekin E, Weissenborn SJ, Wieland U, Dries V, Dienes HP, Eckel HE, Pfister HJ, Fuchs PG (2003) Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162(3):747–753CrossRefGoogle Scholar
  10. 10.
    Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klussmann JP, Turek LP, Haugen TH (2003) Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 104(3):336–344CrossRefGoogle Scholar
  11. 11.
    Bova RJ, Quinn DI, Nankervis JS, Cole IE, Sheridan BF, Jensen MJ et al (1999) Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 5(10):2810–2819PubMedGoogle Scholar
  12. 12.
    Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, Goodman SN, Sidransky D (1995) Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332(7):429–435CrossRefGoogle Scholar
  13. 13.
    Sisk EA, Soltys SG, Zhu S, Fisher SG, Carey TE, Bradford CR (2002) Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck 24(9):841–849CrossRefGoogle Scholar
  14. 14.
    Jenni K Peltonem, Henni M Helppi et al. p53 in head and neck cancers: functional consequences and environmental implications of TP53 mutations. Head Neck Oncol 2010;2:36Google Scholar
  15. 15.
    Chung CH, Zhang Q, Hammond EM, Trotti AM, Wang H, Spencer S et al (2011) Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Radiat Oncol 81(2):331–338CrossRefGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of RadiotherapyMS Ramaiah Medical CollegeBangaloreIndia

Personalised recommendations